15.02.2017 • NewsElaine BurridgeIPOAlzChem

Germany’s AlzChem Postpones IPO

(c) Alzchem
(c) Alzchem

German chemical producer AlzChem has decided to postpone its planned initial public offering (ipo), blaming political issues for causing persistent uncertainty for new investments. Trading of AlzChem’s shares was originally planned to start on the Frankfurt Stock Exchange on Feb. 10.

The Bavarian company, which manufactures products based on the nitrogen-carbon-nitrogen (NCN) chain, was planning to raise between €40 million and €50 million from the IPO, with most of the proceeds to be invested in a new specialty chemical plant at its base in Trostberg. AlzChem said it will now make use of alternative financing possibilities to fund further growth and will re-evaluate an IPO at a later date.

Formerly part of Evonik before being sold to an investment fund in 2009, AlzChem has a leading position in selected niche markets, including feed additives and food supplements. It has four production sites in Germany, a carbide plant in Sweden, as well as subsidiaries in the US and China, employing nearly 1,500 people altogether.

 

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.